Eli Lilly Says Clinical Trial Success Propels Ataibeckley Lead Program into Phase 3

Dow Jones07-16 19:07

AtaiBeckley's lead asset, BPL-003, has initiated Phase three activities for treatment-resistant depression after receiving Breakthrough Therapy Designation from the FDA. The compound is a synthetic form of 5-MeO-DMT administered intranasally. In a Phase 2b study, BPL-003 demonstrated rapid and durable reductions in depressive symptoms following an in-clinic visit lasting approximately two hours on average, with effects persisting for months. The program targets patients whose depression hasn't responded to multiple treatments. VLS-01, a buccal film formulation of DMT, is also advancing in an ongoing Phase 2b study

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

July 16, 2026 07:07 ET (11:07 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment